Literature DB >> 25103356

Natural killer T cells: drivers or passengers in preventing human disease?

Stuart P Berzins1, David S Ritchie2.   

Abstract

Natural killer T (NKT) cells are credited with regulatory roles in immunity against cancers, autoimmune diseases, allergies, and bacterial and viral infections. Studies in mice and observational research in patient groups have suggested that NKT cell-based therapies could be used to prevent or treat these diseases, yet the translation into clinical settings has been disappointing. We support the view that NKT cells have regulatory characteristics that could be exploited in clinical settings, but there are doubts about the natural roles of NKT cells in vivo and whether NKT cell defects are fundamental drivers of disease in humans. In this Opinion article, we discuss the uncertainties and opportunities regarding NKT cells in humans, and the potential for NKT cells to be manipulated to prevent or treat disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25103356     DOI: 10.1038/nri3725

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  124 in total

Review 1.  NKT cells: what's in a name?

Authors:  Dale I Godfrey; H Robson MacDonald; Mitchell Kronenberg; Mark J Smyth; Luc Van Kaer
Journal:  Nat Rev Immunol       Date:  2004-03       Impact factor: 53.106

Review 2.  Raising the NKT cell family.

Authors:  Dale I Godfrey; Sanda Stankovic; Alan G Baxter
Journal:  Nat Immunol       Date:  2010-02-07       Impact factor: 25.606

3.  NKT-cell-based immunotherapies in clinical trials.

Authors:  Mark A Exley; Toshinori Nakayama
Journal:  Clin Immunol       Date:  2011-04-28       Impact factor: 3.969

4.  Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells.

Authors:  T Kawano; J Cui; Y Koezuka; I Toura; Y Kaneko; H Sato; E Kondo; M Harada; H Koseki; T Nakayama; Y Tanaka; M Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

5.  A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.

Authors:  Shinichiro Motohashi; Aki Ishikawa; Eiichi Ishikawa; Mizuto Otsuji; Toshihiko Iizasa; Hideki Hanaoka; Naomi Shimizu; Shigetoshi Horiguchi; Yoshitaka Okamoto; Shin-ichiro Fujii; Masaru Taniguchi; Takehiko Fujisawa; Toshinori Nakayama
Journal:  Clin Cancer Res       Date:  2006-10-06       Impact factor: 12.531

Review 6.  Mucosal-associated invariant T cells: unconventional development and function.

Authors:  Lionel Le Bourhis; Lucia Guerri; Mathilde Dusseaux; Emmanuel Martin; Claire Soudais; Olivier Lantz
Journal:  Trends Immunol       Date:  2011-04-02       Impact factor: 16.687

7.  Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes.

Authors:  Shin-ichiro Fujii; Kanako Shimizu; Virginia Klimek; Matthew D Geller; Stephen D Nimer; Madhav V Dhodapkar
Journal:  Br J Haematol       Date:  2003-08       Impact factor: 6.998

8.  CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma.

Authors:  Omid Akbari; John L Faul; Elisabeth G Hoyte; Gerald J Berry; Jan Wahlström; Mitchell Kronenberg; Rosemarie H DeKruyff; Dale T Umetsu
Journal:  N Engl J Med       Date:  2006-03-16       Impact factor: 91.245

9.  Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors.

Authors:  Gabriel Bricard; Valerie Cesson; Estelle Devevre; Hanifa Bouzourene; Catherine Barbey; Nathalie Rufer; Jin S Im; Pedro M Alves; Olivier Martinet; Nermin Halkic; Jean-Charles Cerottini; Pedro Romero; Steven A Porcelli; H Robson Macdonald; Daniel E Speiser
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

10.  Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients.

Authors:  David H Chang; Keren Osman; John Connolly; Anjli Kukreja; Joseph Krasovsky; Maggi Pack; Aisha Hutchinson; Matthew Geller; Nancy Liu; Rebecca Annable; Jennifer Shay; Kelly Kirchhoff; Nobusuke Nishi; Yoshitaka Ando; Kunihiko Hayashi; Hani Hassoun; Ralph M Steinman; Madhav V Dhodapkar
Journal:  J Exp Med       Date:  2005-05-02       Impact factor: 14.307

View more
  31 in total

1.  Activation of glioma cells generates immune tolerant NKT cells.

Authors:  Bo Tang; Wei Wu; Xiaowei Wei; Yang Li; Gang Ren; Wenhai Fan
Journal:  J Biol Chem       Date:  2014-10-23       Impact factor: 5.157

Review 2.  Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy.

Authors:  Huang Zhu; Yi-Shin Lai; Ye Li; Robert H Blum; Dan S Kaufman
Journal:  Stem Cells       Date:  2018-01-03       Impact factor: 6.277

3.  MHC I-related chain a expression in gastric carcinoma and the efficacy of immunotherapy with cytokine-induced killer cells.

Authors:  Yu Chen; Jing Lin; Zeng-Qing Guo; Wan-Song Lin; Zhi-Feng Zhou; Chuang-Zhong Huang; Qiang Chen; Yun-Bin Ye
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

Review 4.  Spectrum of T-lymphocyte activities regulating allergic lung inflammation.

Authors:  Erwin W Gelfand; Anthony Joetham; Meiqin Wang; Katsuyuki Takeda; Michaela Schedel
Journal:  Immunol Rev       Date:  2017-07       Impact factor: 12.988

5.  Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis.

Authors:  Diana Groza; Sebastian Gehrig; Pavol Kudela; Martin Holcmann; Christine Pirker; Carina Dinhof; Hemma H Schueffl; Marek Sramko; Julia Hoebart; Fatih Alioglu; Michael Grusch; Manfred Ogris; Werner Lubitz; Bernhard K Keppler; Irena Pashkunova-Martic; Christian R Kowol; Maria Sibilia; Walter Berger; Petra Heffeter
Journal:  Oncoimmunology       Date:  2018-02-16       Impact factor: 8.110

Review 6.  Coevolution of T-cell receptors with MHC and non-MHC ligands.

Authors:  Caitlin D Castro; Adrienne M Luoma; Erin J Adams
Journal:  Immunol Rev       Date:  2015-09       Impact factor: 12.988

Review 7.  mTOR and its tight regulation for iNKT cell development and effector function.

Authors:  Wei Yang; Balachandra Gorentla; Xiao-Ping Zhong; Jinwook Shin
Journal:  Mol Immunol       Date:  2015-08-04       Impact factor: 4.407

8.  STAT3 promotes CD1d-mediated lipid antigen presentation by regulating a critical gene in glycosphingolipid biosynthesis.

Authors:  Abhirami K Iyer; Jianyun Liu; Richard M Gallo; Mark H Kaplan; Randy R Brutkiewicz
Journal:  Immunology       Date:  2015-09-21       Impact factor: 7.397

Review 9.  Cancer-derived exosomic microRNAs shape the immune system within the tumor microenvironment: State of the art.

Authors:  Francesca Fanini; Muller Fabbri
Journal:  Semin Cell Dev Biol       Date:  2016-12-09       Impact factor: 7.727

Review 10.  Aberrant miRNAs Regulate the Biological Hallmarks of Glioblastoma.

Authors:  Wanli Yu; Sai Liang; Chunzhi Zhang
Journal:  Neuromolecular Med       Date:  2018-09-04       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.